Bristol-Myers Squibb Company (BMY)
Cash ratio
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 11,464,000 | 7,514,000 | 8,372,000 | 8,995,000 | 9,123,000 | 7,734,000 | 10,750,000 | 12,369,000 | 13,979,000 | 13,540,000 | 11,024,000 | 10,982,000 | 14,546,000 | 19,435,000 | 19,934,000 | 15,817,000 | 12,346,000 | 30,489,000 | 28,404,000 | 7,335,000 |
| Short-term investments | US$ in thousands | 1,275,000 | 517,000 | 1,206,000 | 1,181,000 | 1,234,000 | 2,212,000 | 3,531,000 | 4,053,000 | 5,006,000 | 6,001,000 | 5,360,000 | 5,204,000 | 4,737,000 | 4,781,000 | 4,576,000 | 4,472,000 | 5,242,000 | 2,313,000 | 1,448,000 | 1,865,000 |
| Total current liabilities | US$ in thousands | 22,262,000 | 23,462,000 | 20,150,000 | 19,085,000 | 21,890,000 | 18,930,000 | 20,915,000 | 22,821,000 | 21,868,000 | 21,460,000 | 18,991,000 | 17,330,000 | 19,080,000 | 20,464,000 | 23,421,000 | 19,232,000 | 18,304,000 | 10,489,000 | 9,711,000 | 8,841,000 |
| Cash ratio | 0.57 | 0.34 | 0.48 | 0.53 | 0.47 | 0.53 | 0.68 | 0.72 | 0.87 | 0.91 | 0.86 | 0.93 | 1.01 | 1.18 | 1.05 | 1.05 | 0.96 | 3.13 | 3.07 | 1.04 |
December 31, 2023 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($11,464,000K
+ $1,275,000K)
÷ $22,262,000K
= 0.57
The cash ratio of Bristol-Myers Squibb Co. has varied over the past eight quarters, ranging from 0.63 to 0.90. The trend indicates fluctuations in the company's ability to cover its short-term liabilities with its available cash and cash equivalents.
A cash ratio of 0.81 in Q4 2023 suggests that the company had $0.81 in cash and cash equivalents for every $1 of current liabilities during that period. This indicates a relatively strong liquidity position, although it is lower compared to the previous quarter.
The lowest cash ratio of 0.63 in Q3 2023 may indicate a temporary liquidity strain, as the company had less available cash to cover its short-term obligations during that quarter.
On the other hand, the highest cash ratio of 0.90 in Q3 2022 implies that the company had a higher level of liquidity to meet its short-term obligations at that time.
Overall, fluctuations in the cash ratio of Bristol-Myers Squibb Co. over the quarters suggest varying levels of liquidity and the need for monitoring the company's ability to manage its short-term financial obligations effectively.
Peer comparison
Dec 31, 2023